A comparison of immunotherapy delivery methods for allergen immunotherapy.

about

Immunobiology of critical pediatric asthma.The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases.Twenty years' observation of subcutaneous pollen allergoid immunotherapy efficacy in adults.

P2860

Q38181015-DA063D89-33E9-4406-A3A4-3C0380076C64 Q38259275-ABCE0D23-B5AE-4F60-B1CD-FF6822EDC2E7 Q49734725-FA5A8556-1A56-46E1-AA76-B2A783CA7122

P2860

A comparison of immunotherapy delivery methods for allergen immunotherapy.

Item

http://www.wikidata.org/entity/Q38103286

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

A comparison of immunotherapy delivery methods for allergen immunotherapy.

@en

type

Item

label

A comparison of immunotherapy delivery methods for allergen immunotherapy.

@en

prefLabel

A comparison of immunotherapy delivery methods for allergen immunotherapy.

@en

P1476

A comparison of immunotherapy delivery methods for allergen immunotherapy.

@en

P2093

Ludger Klimek

http://www.w3.org/2001/XMLSchema#string

Oliver Pfaar

http://www.w3.org/2001/XMLSchema#string

P2860

Environmental exposure to endotoxin and its relation to asthma in school-age children

Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys

Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.

Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.

CpG DNA as a vaccine adjuvant.

Immunotherapeutic uses of CpG oligodeoxynucleotides.

P304

465-74; quiz 475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1586/ECI.13.25

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236601288

http://www.w3.org/2001/XMLSchema#string

P698

23634740

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

A comparison of immunotherapy delivery methods for allergen immunotherapy.

about

P2860

P2860

A comparison of immunotherapy delivery methods for allergen immunotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921